{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:27:57Z","timestamp":1790720877077,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.transci.2023.103830","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:06:53Z","timestamp":1697062013000},"page":"103830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection"],"prefix":"10.1016","volume":"62","author":[{"given":"F.","family":"Lanza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Zannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.transci.2023.103830_bib1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/bmt.2017.34","article-title":"M. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"10.1016\/j.transci.2023.103830_bib2","first-page":"244.e1","article-title":"Low dose cyclophosphamide versus intermediate-high dose cyclophosphamide versus G-CSF alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"10.1016\/j.transci.2023.103830_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102785","article-title":"New Horizons on stem cell cryopreservation through the artificial eyes of CD 34+, using modern flow cytometry tools","volume":"59","author":"Lanza","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.transci.2023.103830_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clgc.2016.06.013","article-title":"European society for blood and marrow transplantation (EBMT) solid tumors working party. Salvage high-dose chemotherapy for relapsed pure seminoma in the last 10 Years: results from the European Society for Blood and Marrow Transplantation Series 2002-2012","volume":"15","author":"Necchi","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.transci.2023.103830_bib5","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2023.103830_bib6","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.transci.2023.103830_bib7","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","article-title":"Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"20","author":"Duong","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"10.1016\/j.transci.2023.103830_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transpl"},{"issue":"17","key":"10.1016\/j.transci.2023.103830_bib9","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1182\/blood-2011-06-318220","article-title":"How I treat patients who mobilize hematopoietic stem cells poorly","volume":"118","author":"Bik To","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.transci.2023.103830_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbmt.2017.10.008","article-title":"Chemotherapy-based stem cell mobilization does not result in significant paraprotein reduction in myeloma patients in the era of novel induction regimens","volume":"24","author":"Oyekunle","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103830_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100771","article-title":"Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization","volume":"47","author":"Chen","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.transci.2023.103830_bib12","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2023.103830_bib13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/bmt.2015.23","article-title":"G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis","volume":"50","author":"Antar","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103830_bib14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bmt.2015.322","article-title":"Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study","volume":"51","author":"Afifi","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103830_bib15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/bmt.2013.52","article-title":"Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies","volume":"48","author":"Awan","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103830_bib16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bmt.2010.170","article-title":"Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103830_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2012.08.010","article-title":"Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization","volume":"19","author":"Micallef","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"10.1016\/j.transci.2023.103830_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/trf.12265","article-title":"Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma","volume":"54","author":"Lanza","year":"2014","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.transci.2023.103830_bib19","doi-asserted-by":"crossref","first-page":"E557","DOI":"10.1002\/ajh.24817","article-title":"A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach","volume":"92","author":"Lanza","year":"2017","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.transci.2023.103830_bib20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo","volume":"47","author":"Olivieri","year":"2012","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"10.1016\/j.transci.2023.103830_bib21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41409-017-0033-0","article-title":"Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis","volume":"53","author":"Mohty","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.transci.2023.103830_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41409-017-0051-y","article-title":"Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score","volume":"53","author":"Olivieri","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.transci.2023.103830_bib23","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41409-019-0676-0","article-title":"Results from a multicenter, non interventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor","volume":"55","author":"Morris","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103830_bib24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbmt.2010.08.018","article-title":"Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide","volume":"17","author":"Shaughnessy","year":"2011","journal-title":"Biol Blood Marrow"},{"key":"10.1016\/j.transci.2023.103830_bib25","first-page":"42","article-title":"Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma","volume":"59","author":"Milone","year":"2018","journal-title":"LeukLymphoma"},{"issue":"8","key":"10.1016\/j.transci.2023.103830_bib26","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41409-021-01251-8","article-title":"Chemotherapy-based versus chemotherapy-free stem cell mobilization (\u00b1 plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis","volume":"56","author":"Lazzaro","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.transci.2023.103830_bib27","doi-asserted-by":"crossref","DOI":"10.5812\/ijcm-120241","article-title":"Evaluation of CD34+ cell count at different time points following plerixafor administration in autologous hematopoietic stem cell transplantation","volume":"15","author":"Tavakoli Ardakani","year":"2022","journal-title":"Int J Cancer Manag"},{"issue":"2","key":"10.1016\/j.transci.2023.103830_bib28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/10428194.2018.1485911","article-title":"Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study","volume":"60","author":"Valtola","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.transci.2023.103830_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102753","article-title":"Manipulation, and cryopreservation of autologous peripheral blood stem cell products in Italy: a survey by GITMO, SIDEM and GIIMA societies","volume":"59","author":"Lanza","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2023.103830_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jclinepi.2021.09.028","article-title":"A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations","volume":"141","author":"Lotfi","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.transci.2023.103830_bib31","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.7326\/M22-0514","article-title":"Framework for the development of living practice guidelines in health care","volume":"175","author":"El Mikati","year":"2022","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.transci.2023.103830_bib32","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1182\/bloodadvances.2021005149","article-title":"Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors","volume":"6","author":"Xiang","year":"2022","journal-title":"Blood Adv"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223002458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223002458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:55:44Z","timestamp":1761468944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050223002458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1473050223002458"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2023.103830","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2023.103830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103830"}}